{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:50:36Z","timestamp":1790128236594,"version":"4.0.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"am","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["U54AG044170"],"award-info":[{"award-number":["U54AG044170"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["K08AI141765"],"award-info":[{"award-number":["K08AI141765"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jaip.2022.08.013","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T23:48:03Z","timestamp":1660780083000},"page":"3149-3155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Safety of Biologics for Atopic Diseases During Pregnancy"],"prefix":"10.1016","volume":"10","author":[{"given":"Fnu","family":"Shakuntulla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0445-4929","authenticated-orcid":false,"given":"Sergio E.","family":"Chiarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2022.08.013_bib1","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/all.15063","article-title":"Management of allergic diseases in pregnancy","volume":"77","author":"Pfaller","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2022.08.013_bib2","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/j.1471-0528.2011.03055.x","article-title":"A\u00a0meta-analysis of adverse perinatal outcomes in women with asthma","volume":"118","author":"Murphy","year":"2011","journal-title":"BJOG"},{"key":"10.1016\/j.jaip.2022.08.013_bib3","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/1471-0528.12224","article-title":"The risk of congenital malformations, perinatal mortality and neonatal hospitalisation among pregnant women with asthma: a systematic review and meta-analysis","volume":"120","author":"Murphy","year":"2013","journal-title":"BJOG"},{"key":"10.1016\/j.jaip.2022.08.013_bib4","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaci.2014.08.025","article-title":"The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy","volume":"135","author":"Namazy","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.08.013_bib5","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jaci.2019.05.019","article-title":"Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort","volume":"145","author":"Namazy","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.08.013_bib6","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.3906\/sag-2101-341","article-title":"Country-based report: the safety of omalizumab treatment in pregnant patients with asthma","volume":"51","author":"Gemicio\u011flu","year":"2021","journal-title":"Turk J Med Sci"},{"key":"10.1016\/j.jaip.2022.08.013_bib7","doi-asserted-by":"crossref","first-page":"104","DOI":"10.5114\/pdia.2014.40975","article-title":"Omalizumab in pregnant women treated due to severe asthma: two case reports of good outcomes of pregnancies","volume":"31","author":"Kupry\u015b-Lipi\u0144ska","year":"2014","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.jaip.2022.08.013_bib8","first-page":"1683","article-title":"A\u00a0case of an asthma patient receiving omalizumab during pregnancy [in Japanese]","volume":"61","author":"Hirashima","year":"2012","journal-title":"Arerugi"},{"issue":"Suppl 2","key":"10.1016\/j.jaip.2022.08.013_bib9","first-page":"S106","article-title":"273 fetal loss in severe asthma and posterior healthy pregnancy and birth with the use of omalizumab\u2014case report","volume":"5","author":"Kuschnir","year":"2012","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2022.08.013_bib10","first-page":"364","article-title":"Omalizumab and pregnancy: a case report: 974","volume":"68","author":"Cortese","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2022.08.013_bib11","doi-asserted-by":"crossref","first-page":"515","DOI":"10.4168\/aair.2021.13.3.515","article-title":"Safety of omalizumab during pregnancy and breast-feeding with assessment of placental transfer: a case report","volume":"13","author":"Majou","year":"2021","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaip.2022.08.013_bib12","series-title":"Pregnancy and infant outcomes among pregnant women with chronic spontaneous urticaria (CSU) treated with omalizumab: a descriptive analysis from the EXPECT pregnancy registry","author":"Namazy","year":"2021"},{"key":"10.1016\/j.jaip.2022.08.013_bib13","first-page":"145","article-title":"Omalizumab use during pregnancy for CIU: a tertiary care experience","volume":"48","author":"Cuervo-Pardo","year":"2016","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.08.013_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.652973","article-title":"Case report: omalizumab for chronic spontaneous urticaria in pregnancy","volume":"12","author":"Liao","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2022.08.013_bib15","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000509179","article-title":"Omalizumab use in chronic spontaneous urticaria during pregnancy and a four years\u2019 follow-up: a case report","volume":"12","author":"Losappio","year":"2020","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.jaip.2022.08.013_bib16","doi-asserted-by":"crossref","first-page":"326","DOI":"10.18176\/jiaci.0179","article-title":"Omalizumab as third-line therapy for urticaria during pregnancy","volume":"27","author":"Ensina","year":"2017","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2022.08.013_bib17","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/368053","article-title":"Successful and safe treatment of chronic spontaneous urticaria with omalizumab in a woman during two consecutive pregnancies","volume":"2015","author":"Ghazanfar","year":"2015","journal-title":"Case Rep Med"},{"key":"10.1016\/j.jaip.2022.08.013_bib18","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1111\/jdv.14034","article-title":"Omalizumab use during pregnancy for chronic spontaneous urticaria (CSU): report of two cases","volume":"31","author":"Gonzalez-Medina","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2022.08.013_bib19","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1080\/07853890.2021.1900591","article-title":"May mepolizumab used in asthma correct subfertility?","volume":"53","author":"Ozden","year":"2021","journal-title":"Ann Med"},{"key":"10.1016\/j.jaip.2022.08.013_bib20","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.jaip.2020.11.060","article-title":"Successful pregnancy in the setting of eosinophil depletion by benralizumab","volume":"9","author":"Manetz","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.08.013_bib21","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/j.anai.2018.09.300","article-title":"Breathing for two: a case of severe eosinophilic asthma during pregnancy treated with benralizumab","volume":"121","author":"Saco","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2022.08.013_bib22","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/ced.14725","article-title":"Paternal and maternal use of dupilumab in patients with atopic dermatitis: a case series","volume":"46","author":"Bosma","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaip.2022.08.013_bib23","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1159\/000515246","article-title":"Atopic dermatitis treated safely with dupilumab during pregnancy: a case report and review of the literature","volume":"13","author":"Lobo","year":"2021","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.jaip.2022.08.013_bib24","doi-asserted-by":"crossref","first-page":"e256","DOI":"10.1111\/jdv.16235","article-title":"A\u00a0case of atopic eczema treated safely with dupilumab during pregnancy and lactation","volume":"34","author":"Kage","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2022.08.013_bib25","doi-asserted-by":"crossref","first-page":"E484","DOI":"10.1111\/1346-8138.16033","article-title":"Case of atopic eczema treated with dupilumab throughout conception, pregnancy, and lactation","volume":"48","author":"Kage","year":"2021","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaip.2022.08.013_bib26","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jdcr.2020.08.001","article-title":"Dupilumab for the treatment of severe atopic dermatitis in a pregnant patient: a case report","volume":"6","author":"Mian","year":"2020","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaip.2022.08.013_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15237","article-title":"Patient with atopic dermatitis, hyper IgE syndrome and ulcerative colitis, treated successfully with dupilumab during pregnancy","volume":"35","author":"Gracia-Darder","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaip.2022.08.013_bib28","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/ced.15049","article-title":"Severe atopic dermatitis treated successfully with dupilumab throughout pregnancy","volume":"47","author":"Costley","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaip.2022.08.013_bib29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13223-022-00650-w","article-title":"The use of dupilumab in severe atopic dermatitis during pregnancy: a case report","volume":"18","author":"Akhtar","year":"2022","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2022.08.013_bib30","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/ced.14765","article-title":"Treatment of pemphigoid gestationis with dupilumab","volume":"46","author":"Riquelme-Mc Loughlin","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaip.2022.08.013_bib31","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1111\/1346-8138.14869","article-title":"Successful control of severe eosinophilic granulomatosis with polyangiitis in a pregnancy and perinatal period: A use of mepolizumab","volume":"46","author":"Kasuya","year":"2019","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaip.2022.08.013_bib32","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2125.2009.03401.x","article-title":"Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma","volume":"68","author":"Lowe","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaip.2022.08.013_bib33","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1016\/j.jaip.2020.05.054","article-title":"Omalizumab concentrations in pregnancy and lactation: a case study","volume":"8","author":"Saito","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.08.013_bib34","series-title":"Global strategy for asthma management and prevention","year":"2022"},{"key":"10.1016\/j.jaip.2022.08.013_bib35","series-title":"Omalizumab full prescribing information\/FDA access data","year":"2021"},{"key":"10.1016\/j.jaip.2022.08.013_bib36","series-title":"Birth defects\/Data and statistics\/CDC reports","year":"2008"},{"key":"10.1016\/j.jaip.2022.08.013_bib37","series-title":"Rate of low birth weight and preterm birth rate in U.S.\/CDC report","year":"2022"},{"key":"10.1016\/j.jaip.2022.08.013_bib38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/11584340-000000000-00000","article-title":"Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody","volume":"50","author":"Smith","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jaip.2022.08.013_bib40","series-title":"Mepolizumab full prescribing information\/FDA access data","year":"2021"},{"key":"10.1016\/j.jaip.2022.08.013_bib41","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1080\/17425255.2017.1359253","article-title":"Pharmacokinetic\/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma","volume":"13","author":"Matera","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.jaip.2022.08.013_bib43","series-title":"Benralizumab full prescribing information\/FDA access data","year":"2017"},{"key":"10.1016\/j.jaip.2022.08.013_bib44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.rmed.2019.05.005","article-title":"Monoclonal antibodies for severe asthma: pharmacokinetic profiles","volume":"153","author":"Matera","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2022.08.013_bib45","first-page":"564","article-title":"Reslizumab (Cinqair): an interleukin-5 antagonist for severe asthma of the eosinophilic phenotype","volume":"42","author":"Hom","year":"2017","journal-title":"P\u00a0T"},{"key":"10.1016\/j.jaip.2022.08.013_bib46","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s13555-020-00457-w","article-title":"Immunosuppressive and immunomodulating therapy for atopic dermatitis in pregnancy: an appraisal of the literature","volume":"10","author":"Heilskov","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaip.2022.08.013_bib48","series-title":"Dupilumab and pregnancy outcomes: a retrospective cohort study using administrative healthcare databases","year":"2019"},{"key":"10.1016\/j.jaip.2022.08.013_bib49","series-title":"Dupilumab full prescribing information\/FDA access data","year":"2019"},{"key":"10.1016\/j.jaip.2022.08.013_bib50","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.clinthera.2020.11.014","article-title":"Tezepelumab pharmacokinetics, safety, and tolerability after administration via vial-and-syringe, accessorized prefilled syringe, or autoinjector: a randomized trial in healthy volunteers","volume":"43","author":"Zheng","year":"2021","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaip.2022.08.013_bib51","series-title":"Tezepelumab full prescribing information\/FDA access data","year":"2021"},{"key":"10.1016\/j.jaip.2022.08.013_bib52","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","article-title":"Atopic dermatitis is an IL-13-dominant disease with greater molecular heterogeneity compared to psoriasis","volume":"139","author":"Tsoi","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2022.08.013_bib53","series-title":"Tralokinumab full prescribing information\/FDA access data","year":"2021"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822008170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822008170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:35:27Z","timestamp":1761975327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219822008170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2213219822008170"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2022.08.013","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of Biologics for Atopic Diseases During Pregnancy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2022.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}